Revolution Medicines (RVMD) Equity Average (2019 - 2026)

Revolution Medicines' Equity Average history runs 8 years deep, the most recent figure standing at $1.6 billion for Q1 2026.

• In Q1 2026, Equity Average fell 27.91% year-over-year to $1.6 billion; the TTM figure through Mar 2026 stood at $1.6 billion (down 27.91% YoY), while the FY2025 annual figure was $1.9 billion, down 4.76% from the prior year.
• Equity Average was $1.6 billion for Q1 2026 at Revolution Medicines, down from $1.6 billion in the prior quarter.
• In the past five years, Equity Average ranged from a high of $2.2 billion in Q1 2025 to a low of $524.9 million in Q2 2022.
• Historically, Equity Average has averaged $1.3 billion across 5 years, with a median of $1.6 billion in 2026.
• The sharpest annual moves came in 2024 and 2026: Equity Average surged 116.91% in 2024, then retreated 27.91% in 2026.
• A 5-year view of Equity Average shows it stood at $683.3 million in 2022, then surged by 94.91% to $1.3 billion in 2023, then jumped by 43.84% to $1.9 billion in 2024, then declined by 15.75% to $1.6 billion in 2025, then fell by 3.0% to $1.6 billion in 2026.
• The last three Equity Average figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.7 billion (Q3 2025), per Business Quant data.